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Gordon Lowe, MD,† Ann Rumley, PhD,† Kirsten Shuler, BSc,*
Fergus Doubal, MBChB, PhD,*‡ and Joanna M. Wardlaw, FRCR, FRCP, MD, FMedSci*
Background and Objective: Recent studies suggest perivascular spaces are a marker
of small vessel disease, blood–brain barrier permeability, and inflammation, but
little is known about their risk factors and associations with peripheral blood markers.
Materials and Methods: In prospectively recruited patients with recent minor isch-
emic stroke, we investigated the influence of age, sex, hypertension, diabetes, and
smoking on the severity of perivascular spaces in the basal ganglia seen on T2-
weighted magnetic resonance imaging. We assessed plasma markers of endothelial
function (von Willebrand factor, intracellular adhesion molecule-1), inflammation
(interleukin-6, tumor necrosis factor-alpha, C-reactive protein), and thrombosis (fi-
brinogen, prothrombin fragments 1 + 2, thrombin–antithrombin complex, tissue
plasminogen activator, D-dimer). We used a validated semi-automated method
to measure basal ganglia perivascular spaces count and volume. We tested uni-
and multivariable associations between blood markers and basal ganglia perivas-
cular spaces count and volume. Findings: In 100 patients (median age: 67 years,
range: 37-92), on adjusted analysis, basal ganglia perivascular spaces count was
associated with age (r = .117, P = .003) and hypertension (r = 2.225, P = .013). On
multivariable linear regression, adjusted for age, sex, hypertension, smoking and
diabetes, reduced von Willebrand factor was associated with increased basal ganglia
perivascular spaces count (r = −.025, P = .032). Conclusion: The association of in-
creased basal ganglia perivascular spaces count with reduced von Willebrand factor
is novel. As von Willebrand factor may promote cerebral endothelial integrity, in-
sufficient von Willebrand factor is consistent with dysfunctional cerebral endothelium
and increased basal ganglia perivascular spaces in cerebral small vessel disease.
Quantitative perivascular spaces measurement may increase sensitivity to detect
cerebral endothelial dysfunction. Key Words: Endothelial function—stroke—small
vessel disease—perivascular spaces.
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Introduction
Perivascular spaces (PVS), or Virchow–Robin spaces,
are pial extensions of the subarachnoid space that sur-
round the arteries, arterioles, veins, and venules as they
penetrate the brain parenchyma.1,2 PVS are an impor-
tant drainage conduit for soluble and insoluble material
through the central nervous system.3 Many inflammato-
ry processes take place in PVS; for example, PVS are a
specific site for immune cell accumulation, reaction, and
transmigration into the brain parenchyma (e.g., leuko-
cytes, dendritic cells, T-cells, B-cells, and macrophages4-6).
PVS on magnetic resonance imaging (MRI) are an
imaging marker for cerebral small vessel disease (SVD).7-9
PVS are associated with other SVD features, such as white
matter hyperintensities (WMH), atrophy, microbleeds,
lacunes, and recent small subcortical infarcts.10 Increas-
ing numbers of PVS were also associated with increased
blood–brain barrier (BBB) permeability in stroke patients,11
worse cognitive function in older people,12 and more WMH
in older subjects13 and in patients with stroke.7,8
Blood marker levels in the peripheral circulation could
reflect endothelial function, inflammation, and thrombo-
sis changes in the brain, and are associated with SVD
features such as WMH and lacunar stroke.14 However,
only four studies explored the associations between blood
markers and PVS.13,15,16 More PVS in the basal ganglia (BG)
regions were associated with higher plasma oxidized low-
density lipoprotein in adjusted analysis, suggesting that
oxidized low-density lipoprotein may contribute to PVS
progression through endothelial dysfunction and anti-
body formation.16 Associations between more BG PVS and
higher plasma neopterin (from activated monocytes or
macrophages),15 plasma interleukin-6 (IL-6),17 and plasma
C-reactive protein13 suggested associations with inflam-
mation in patients with stroke,15,16 vascular disease,17 and
older community-dwelling individuals,13 respectively.
These studies used visual assessment of PVS that re-
flects the number of visible PVS, but PVS may increase
in size as well as in number, and the visual score may
lack sensitivity in detecting associations with plasma
markers. We developed a computational quantitative
method to measure PVS volume and number.18 As it is
unclear if PVS reflect primarily inflammation, endothe-
lial dysfunction, thrombosis, or all three, in the present
analysis we test associations between PVS count and
volume and plasma markers of endothelial function, in-
flammation, and thrombosis in the chronic phase after
lacunar stroke or mild cortical stroke.
Methods
Patient Recruitment and Assessment
We used data from 100 patients recruited prospective-
ly with lacunar or minor (i.e., non-disabling) cortical ischemic
stroke who participated in a study of BBB permeability.19
All patients were carefully examined by an experienced
stroke physician who recorded the full medical history
and risk factors, including hypertension, diabetes, smoking,
heart disease, and cholesterol. All patients had diagnos-
tic brain MRI, including sagittal T1-weighted and axial
diffusion-weighted imaging, T2-weighted, fluid-attenuated
inversion recovery, and gradient-echo sequences ac-
quired on a GE Signa scanner (General Electric Medical
Systems, Milwaukee, Wisconsin, USA) at 1.5T, to classify
final stroke subtype and qualitatively assess PVS (se-
quence details published previously7,19). All patients received
guideline-based stroke secondary prevention (clopidogrel,
statin in all, and antihypertensive drugs in patients with
hypertension). All patients gave written informed consent
to participate in the study and the study was approved
by the local ethics committee.
MRI Data Analysis
All image processing was performed blind to clinical
and blood marker details. We used a semi-automated
method to measure BG PVS count and volume.18 This
method uses intensity-normalized structural T2-weighted
MRI obtained after performing a linear intensity adjust-
ment with a gamma correction factor of two, followed
by linear mapping to the original images, in MATLAB
(http://www.mathworks.co.uk/help/images/ref/
imadjust.html). We, then, manually applied a standard
region-of-interest extraction, limiting the assessment of
PVS to two bilateral ovoid regions on a representative
BG slice, one in each hemisphere, delineated by the ver-
tical ramus of the lateral fissures and the posterior segment
of the lateral fissures, and automatically extracted PVS
using the Analyze 10.0 software (AnalyzeDirect, Inc., Over-
land Park, Kansas, USA). This method showed a strong
relationship with visual scores, with regression coeffi-
cients of 2.114 (95% confidence interval: 1.364-2.864, P < .001)
for BG PVS count and .022 (95% confidence interval: .012-
.031, P < .001) for BG PVS volume.
Blood Marker Assessment
We collected venous blood from each patient approx-
imately 2 months (minimum of 1 and maximum of 3
months) after stroke to avoid the acute stroke phase. Blood
samples were put immediately into two 2.5-mL
ethylenediaminetetraacetic acid tubes and an 8-mL tube
containing clot activator and gel. The samples were trans-
ferred from the ward on water ice, centrifuged at 2000 g
for 10 minutes, and stored at −80°C until analysis.
Blood marker analysis was performed in an accred-
ited laboratory, blinded to the patients’ clinical and imaging
details. We measured 10 blood markers using high sen-
sitive assays (assay details in Supplementary Table S1):
1) endothelial dysfunction: von Willebrand factor (vWF)
and intracellular adhesion molecule-1;
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2) inflammation: IL-6, tumor necrosis factor-alpha, and
C-reactive protein; and
3) thrombosis: fibrinogen (Fib), prothrombin frag-
ments 1 and 2 (F 1 + 2), thrombin–antithrombin
complex (TAT), tissue plasminogen activator (tPA),
and D-dimer.
Statistical Analysis
Blood marker data were incomplete for 7 of the 100
patients, but all available data were used in the analyses.
We investigated the influence of patients’ demograph-
ics (age, sex, hypertension, smoking, and diabetes) on (1)
PVS severity (count and volume) and (2) blood marker
levels using multivariable linear regression. We then as-
sessed the associations between PVS severity (count and
volume) and blood marker levels using univariable and
multivariable linear regression (adjusted for patients’ de-
mographics). To investigate smoking further, we condensed
the four original categories (non-smoker; recent smoker,
less than a year; long-term light smoker; heavy smoker)
into “never smoked” or “current or ever smoked” and
used this dichotomized smoking variable in most of our
analysis. Smoking status was missing for one patient.
All analyses were performed using Minitab (Minitab
Inc, version 16) (Minitab Inc., State College, Pennsylva-
nia, USA). Alpha level for significance was P < .05.
Results
Of the 100 patients, 51 had lacunar and 49 had corti-
cal ischemic stroke. The mean age was 69 years old,
ranging from 37 to 92 years old. The median National
Institute for Health Stroke Scale score was 2; 62% of pa-
tients had hypertension, 53% had smoking history, and
15% had diabetes. The median time to blood sampling
was 54.4 days (Q1-Q3: 36-74).
BG PVS Count and Volume and Patient Demographics
In the 100 patients, the median of PVS count was 10,
and the median of PVS volume was .09 mL. Univariate
linear regression (Table 1) showed that both BG PVS count
(P = .003) and volume (P = .020) increased with age and
BG PVS count (P = .013) increased in hypertension, al-
though the association between hypertension and BG PVS
volume did not reach significance. No associations were
seen between BG PVS count and volume and gender,
smoking, or diabetes on univariate analysis.
Blood Markers and Patient Demographics
On multivariable analysis, the endothelial function
marker vWF was associated with age (P < .001). The in-
flammatory marker IL-6 (P = .048), and the thrombosis
markers tPA (P = .001) and Fib (P = .016), were associ-
ated with smoking. No significant associations were seen
between any blood markers and sex, hypertension, or di-
abetes (see Supplementary Table S2).
Blood Markers, BG PVS Levels, and Risk Factors
Univariable analysis showed associations between BG
PVS count and thrombosis markers F 1 + 2 (P = .050) and
TAT (P = .013), and between BG PVS volume and TAT
(P = .037), but not with any other blood markers (Sup-
plementary Table S3). After adjusting for age, sex, and
risk factors, the associations between TAT, F 1 + 2, and
BG PVS became non-significant, but the blood endothe-
lial function marker vWF became negatively associated
with BG PVS count (P = .032) (Tables 2 and 3).
Discussion
We found that PVS increased with age and hyperten-
sion on multivariable analysis, but not with smoking or
diabetes. We also found that most of the blood markers
that we studied were not significantly associated with PVS
count and volume, but that there was a negative asso-
ciation between BG PVS count and the endothelial function
marker vWF after adjustment for age and risk factors.
This association was the opposite to what would be ex-
pected if this were simply due to increasing age or
smoking, and supports the concept that endothelial
Table 1. Associations between BG PVS count and volume and patient demographics (age, gender, hypertension, smoking, and
diabetes, univariable linear regression)
Coefficient (95%CI, P) BG PVS count BG PVS volume
Age .117 (.040 to .194, P = .003*) .001 (.000 to .002, P = .020*)
Male sex 1.433 (−.518 to 3.383, P = .148) .023 (−.002 to .047, P = .072)
Hypertension 2.225 (.476 to 3.973, P = .013*) .022 (−.001 to .044, P = .056)
Smoking −.648 (−2.315 to 1.019, P = .442) −.009 (−.030 to .012, P = .383)
Diabetes −.756 (−3.086 to 1.574, P = .521) −.001 (−.031 to .028, P = .920)
Abbreviations: BG, basal ganglia; CI, confidence interval; PVS, perivascular spaces.
BG PVS count: total number of PVS dots in each patient in the selected BG regions; PVS volume: total volume of all the PVS dots; age:
age increase per year; smoking: current or ever smoked versus never smoked.
*P < .05.
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Table 2. Associations between BG PVS count and blood markers after adjusting for patient demographics (age, sex, hypertension, smoking, and diabetes)
Blood marker Blood marker association Age Male sex Hypertension Smoking Diabetes
Endothelial function
vWF (n = 98) −.025 .155 1.364 2.095 −.498 −.576
(−.047, −.002) (.072 to .239) (−.605 to 3.333) (.365 to 3.824) (−2.164 to 1.168) (−2.949 to 1.797)
P = .032* P > .001* P = .172 P = .018* P = .554 P = .631
ICAM-1 (n = 95) −.003 .109 1.259 2.408 −.849 −.440
(−.019 to .013) (.031 to .187) (−.798 to 3.316) (.617 to 4.199) (−2.563 to .866) (−2.950 to 2.070)
P = .747 P = .007* P = .227 P = .009* P = .328 P = .728
Inflammation
IL-6 (n = 97) −.153 .123 1.377 2.158 −.532 −.697
(−.549 to .242) (.044 to .201) (−.646 to 3.401) (.374 to 3.942) (−2.279 to 1.215) (−3.135 to 1.742)
P = .443 P = .003* P = .180 P = .018* P = .547 P = .572
TNF-α (n = 98) −.613 .114 1.290 2.259 −.654 −.710
(−1.650 to .424) (.037 to .192) (−.724 to 3.304) (.502 to 4.016) (−2.346 to 1.037) (−3.121 to 1.701)
P = .243 P = .004* P = .206 P = .012* P = .444 P = .560
CRP (n = 98) −.034 .118 1.473 2.304 −.525 −.801
(−.127 to .060) (.041 to .196) (−.548 to 3.494) (.528 to 4.081) (−2.251 to 1.201) (−3.234 to 1.631)
P = .474 P = .003* P = .151 P = .012* P = .547 P = .514
Thrombosis
Fib (n = 96) −.639 .123 1.371 2.091 −.335 −.649
(−2.175 to .896) (.044 to .201) (−.668 to 3.409) (.309 to 3.872) (−2.102 to 1.431) (−3.087 to 1.788)
P = .410 P = .003* P = .185 P = .022* P = .707 P = .598
F 1 + 2 (n = 98) .002 .111 1.413 2.165 −.507 −.568
(−.002 to .006) (.032 to .190) (−.598 to 3.425) (.395 to 3.935) (−2.234 to 1.220) (−3.019 to 1.883)
P = .424 P = .006* P = .166 P = .017* P = .561 P = .646
TAT (n = 98) .122 .109 1.379 2.069 −.426 −.661
(−.020 to .264) (.032 to .186) (−.609 to 3.366) (.318 to 3.820) (−2.120 to 1.269) (−3.054 to 1.731)
P = .091 P = .006* P = .172 P = .021* P = .619 P = .584
tPA (n = 98) −.074 .116 1.495 2.267 −.475 −.726
(−.351 to .204) (.039 to .194) (−.547 to 3.536) (.495 to 4.040) (−2.279 to 1.330) (−3.152 to 1.700)
P = .600 P = .004* P = .149 P = .013* P = .603 P = .554
D-dimer (n = 98) .001 .116 1.382 2.209 −.634 −.663
(−.003 to .005) (.038 to .194) (−.638 to 3.402) (.440 to 3.979) (−2.337 to 1.068) (−3.105 to 1.779)
P = .661 P = .004* P = .178 P = .015* P = .461 P = .591
Abbreviations: BG, basal ganglia; CRP, C-reactive protein; Fib, fibrinogen; ICAM-1, intracellular adhesion molecule-1; IL-6, interleukin-6; PVS, perivascular spaces; TAT, thrombin–
antithrombin complex; TNF-α, tumor necrosis factor-alpha; tPA, tissue plasminogen activator; vWF, von Willebrand factor.
PVS count: total number of PVS dots in each patient; age: age increase per year; smoking: current or ever smoked.
*P < .05.
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Table 3. Associations between BG PVS volume and blood markers adjusted for patient demographics (age, sex, hypertension, smoking, and diabetes)
Blood marker Blood marker association Age Male sex Hypertension Smoking Diabetes
Endothelial function
vWF (n = 98) 1.28E-04 .001 .022 .021 −.008 3.03E-04
(4.19E-04 to 1.62E-04) (.000 to .002) (−.004 to .047) (−.001 to .043) (−.030 to .013) (−.030 to .031)
P = .383 P = .014* P = .095 P = .065 P = .453 P = .984
ICAM-1 (n = 95) 0.53E-04 .001 .019 .024 −.009 .004
(−1.51E-04 to 2.57E-04) (.000 to .002) (−.007 to .046) (.001 to .047) (−.031 to .013) (−.028 to .036)
P = .606 P = .026* P = .145 P = .038* P = .400 P = .804
Inflammation
IL-6 (n = 97) −2.27E-04 .001 .020 .019 −.010 .002
(−.005 to .005) (.000 to .002) (−.005 to .045) (−.003 to .041) (−.032 to .011) (−.029 to .032)
P = .927 P = .011* P = .113 P = .096 P = .351 P = .908
TNF-α (n = 98) −.002 .001 .021 .022 −.009 −4.18E-04
(−.015 to .011) (.000 to .002) (−.004 to .047) (−.001 to .044) (−.030 to .013) (−.031 to .030)
P = .757 P = .022* P = .100 P = .056 P = .412 P = .978
CRP (n = 98) −2.59E-04 .001 .022 .022 −.008 −.001
(−.001 to .001) (.000 to .002) (−.003 to .048) (.000 to .045) (−.030 to .014) (−.032 to .030)
P = .664 P = .020* P = .087 P = .053 P = .467 P = .945
Thrombosis
Fib (n = 96) −.001 .001 .021 .021 −.007 .001
(−.021 to .018) (.000 to .002) (−.005 to .047) (−.002 to .043) (−.030 to .015) (−.031 to .032)
P = .906 P = .024* P = .116 P = .075 P = .515 P = .971
F 1 + 2 (n = 98) 0.16E-04 .001 .022 .021 −.008 .001
(−0.35E-04 to 0.67E-04) (.000 to .002) (−.004 to .047) (−.001 to .043) (−.029 to .014) (−.030 to .032)
P = .535 P = .031* P = .091 P = .065 P = .490 P = .946
TAT (n = 98) .001 .001 .021 .020 −.007 1.84E-04
(−.001 to .003) (.000 to .002) (−.004 to .047) (−.002 to .042) (−.028 to .015) (−.030 to .031)
P = .163 P = .031* P = .094 P = .078 P = .538 P = .990
tPA (n = 98) −.001 .001 .023 .022 −.006 −.001
(−.005 to .002) (.000 to .002) (−.002 to .049) (.000 to .045) (−.029 to .017) (−.031 to .030)
P = .451 P = .022* P = .075 P = .050* P = .604 P = .974
D-dimer (n = 98) 0.16E-04 .001 .021 .021 −.009 .001
(−0.39E-04 to 0.71E-04) (.000 to .00) (−.004 to .047) (−.001 to .044) (−.030 to .013) (−.030 to .031)
P = .571 P = .023* P = .099 P = .061 P = .414 P = .973
Abbreviations: BG, basal ganglia; CRP, C-reactive protein; Fib, fibrinogen; ICAM-1, intracellular adhesion molecule-1; IL-6, interleukin-6; PVS, perivascular spaces; TAT, thrombin–
antithrombin complex; TNF-α, tumor necrosis factor-alpha; tPA, tissue plasminogen activator; vWF, von Willebrand factor.
PVS count: total number of PVS dots in each patient; age: age increase per year; smoking: current or ever smoked.
*P < .05.
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dysfunction is a contributing factor in the pathogenesis
of cerebral SVD.
High vWF level is considered a sign of endothelial cell
activity. vWF is increased in the plasma of patients who
subsequently develop stroke,20 and with a variety of neu-
rologic conditions such as cerebral malaria21 and severe
head injury.22 The potential protective effect of vWF on
BBB permeability was demonstrated recently in a vWF
knockout mouse model: In normal mice, vWF inhibited
the expression of the tight junction protein claudin-5 and
led to increased BBB permeability, but in the vWF knock-
out mice increased claudin-5 expression alone did not
protect the BBB but was detrimental, suggesting that vWF
may be important for the regulation of cerebral endo-
thelial function and BBB permeability during certain disease
states.23 Lack of vWF expression could, therefore, indi-
cate impaired cerebral endothelial integrity and increased
BBB permeability, consistent with our findings using
gadolinium-enhanced brain MRI in the same population.19
Further examination of the role of vWF is needed as it
may influence BBB function through effects on tight junc-
tion proteins, which are impaired in an SVD model24,25
and are thought to be impaired in human SVD.
Smoking affects some blood markers. In multivari-
able analysis, the inflammatory blood marker IL-6 and
thrombosis blood markers Fib and tPA were signifi-
cantly associated with smoking. However, we did not find
significant associations between PVS and smoking status,
consistent with the 3C-Dijon study of 1818 patients, 108
(<10%) of whom were current smokers,9 whereas in our
study there was a much higher proportion (53%) who
smoked. We were unable to explain the effect of smoking
on blood markers by the 4-year age difference between
smoker and non-smoker. A larger sample is needed to
explore the associations between PVS and smoking.
We drew blood approximately 2 months after onset of
minor stroke, so our results reflect the chronic and not
acute phase after stroke, and we are neither able to
comment on blood markers and time after stroke, nor
can we comment on blood markers and antiplatelet or
other secondary prevention drugs, as all patients were
prescribed routine secondary prevention agents. The as-
sociations between increasing age, hypertension, and BG
PVS count and volume may not have been completely
corrected statistically and may confound the association
of PVS and vWF, both of which normally rise with age.
However, associations with age and hypertension are con-
sistent with previous studies showing that PVS severity
increases with age and hypertension.6,8,9,26-28
The study strengths include the careful blinding of all
analyses and the validated PVS and blood marker quan-
tification methods, and the range of biomarkers assessed
representing three important domains of vascular func-
tion. These PVS associations need to be confirmed in larger
samples, accounting for other factors such as structural
brain volume and SVD markers, demographic and vas-
cular risk factors, and perhaps at a wider range of times
after stroke. They should also examine if relationships
differ for PVS count and PVS volume, as the two fea-
tures may provide different information about the role
of PVS in the pathogenesis of brain disease.
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